FITZSIMMONS
v.
BIOMET ORTHOPEDICS
AI-generated. These summaries, headnotes, and key points are machine-generated and may contain errors or omissions. Always verify against the full opinion text below. Not legal advice.
Mark Fitzsimmons received a defective M2a Magnum hip implant manufactured by Biomet in 2008, which failed and required revision surgery in 2017, leading to his products liability and negligence claims consolidated into a multi-district litigation. The district court partially granted and partially denied Biomet's motions to exclude expert testimony, admitting the biomechanical and design-defect opinions of biomedical engineer Mari Truman while excluding certain novel common-issue opinions and her unsupported taper mismatch opinion, and admitting orthopedic surgeon George Kantor's specific causation and future medical care opinions while excluding his opinion about titanium alloy components causing cobalt-chromium toxicity. The decision established that under Federal Rule of Evidence 702 and *Daubert*, deficiencies in expert testimony methodology or factual support go to weight rather than admissibility unless the opinion lacks a sufficient analytical foundation or reliable methodology.
The court granted in part and denied in part defendants' motions to exclude expert testimony, admitting some opinions while excluding others deemed speculative or new common-issue opinions.
[1] The admission of expert testimony is governed by Rule 702 of the Federal Rules of Evidence, requiring that the expert be qualified, the methodology be reliable, and the t…
[2] The district court serves as a gatekeeper for the admission of scientific testimony to ensure relevance and reliability, but this role does not supplant the adversary sys…
Previewing 2 of 9 headnotes on this case. FLexlaw’s editorially structured points of law — every proposition, pinpointed — are reserved for members.
Join FLexlaw to unlock all legal intelligencePlaintiff Mark Fitzsimmons sued Biomet Orthopedics after his hip implant failed, requiring revision surgery. The case was part of an MDL before being …
The full statement of facts, procedural history, and disposition for this case are member content.
Join FLexlaw to unlock all legal intelligence© FLexlaw, Inc. — AI-generated enrichments are proprietary. All rights reserved.
Explore caselaw by topic → Browse Differential Diagnosis cases and more on FLexlaw
This matter comes before the Court on defendants’ Motions to Exclude expert testimony (Doc. #124; Doc. #125), filed on October 2, 2020. Plaintiff filed Memorandums in Opposition (Doc. #132; Doc. #134) on October 16, 2020, to which defendants filed Replies (Doc. #144; Doc. #145) on November10, 2020. For the reasons set forth below, the motions are granted in part and denied in part.
I.
In December 2008, plaintiff Mark Fitzsimmons underwent a surgical procedure to implant a M2a Magnum Hip System in his left hip. (Doc. #1, ¶ 20.) The M2a Magnum implant was designed, manufactured, marketed, promoted, and sold by defendants (collectively “Biomet”). (Id. ¶¶ 3-5.) Plaintiff’s implant subsequently failed, causing significant metallosis and requiring a revision surgery in April 2017. (Id. ¶ 21.) Plaintiff filed suit against defendants in May 2017, alleging (1) strict products liability, (2) negligence, (3) breach of implied warranties, (4) breach of express warranty, and (5) failure to warn. (Id. pp. 7-
14.) Plaintiff’s case, one of thousands filed against defendants, was consolidated for pretrial proceedings into a Multi-District Litigation (MDL) action in the United States District Court for the Northern District of Indiana. In re: Biomet M2A Magnum Hip Implants Prods. Liab. Litig., 896 F. Supp. 2d 1339 (J.P.M.L. 2012). After considerable pretrial proceedings in the MDL court, including rulings on motions to exclude common-issue expert opinions, this case was transferred back to this district in February 2019. (Doc. #56; Doc. #57.) The parties then engaged in case-specific discovery until September 2020, and the matter is set for trial for March 2021. (Doc. #108.) Now at the summary judgment stage, the parties have filed various motions to exclude case-specific expert opinions, including defendants’ two motions currently before the Court seeking to preclude opinions from Mari Truman (Doc. #124) and George Kantor (Doc. #125).
II.
The admission of expert testimony is governed by Rule 702 of the Federal Rules of Evidence, which provides that: A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if: (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue;
(b) the testimony is based on sufficient facts or data;
(c) the testimony is the product of reliable principles and methods; and
(d) the expert has reliably applied the principles and methods to the facts of the case.
Fed. R. Evid. 702. Rule 702 contemplates that the district court serve as gatekeeper for the admission of scientific testimony in order to ensure that any and all expert testimony is both relevant and reliable. Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 589 (1993); Tampa Bay Water v. HDR Eng’g, Inc., 731 F. 3d 1171, 1183 (11th Cir. 2013). “The Supreme Court did not intend, however, that the gatekeeper role supplant the adversary system or the role of the jury: vigorous cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof are the traditional and appropriate means of attacking shaky but admissible evidence.” McDowell v. Brown, 392 F. 3d 1283, 1299 (11th Cir. 2004) (marks and citations omitted). In determining the admissibility of expert testimony under Rule 702, the Court applies a “rigorous” three-part inquiry. United States v. Frazier, 387 F. 3d 1244, 1260 (11th Cir. 2004) (en banc). Expert testimony is admissible if (1) the expert is qualified to testify on the topic at issue, (2) the methodology used by the expert is sufficiently reliable, and (3) the testimony will assist the trier of fact. Arthrex, Inc., v. Parcus Med.,
LLC, 2014 WL 3747598, *1 (M.D. Fla. July 29, 2014) (citing Tampa Bay Water, 731 F. 3d at 1183). The burden of laying the proper foundation for the admission of expert testimony “is on the party offering the expert, and the admissibility must be shown by a preponderance of the evidence.” Kilpatrick v. Breg, Inc., 613 F. 3d 1329, 1335 (11th Cir. 2010) (quoting McCorvey v. Baxter Healthcare Corp., 298 F. 3d 1253, 1256 (11th Cir. 2002)). The admission of expert testimony is a matter within the discretion of the district court, which is accorded considerable leeway in making its determination. Frazier, 387 F. 3d at 1258.
III.
A. Mari Truman
Mari Truman is a biomedical engineer with a B.S.E. in biomedical engineering and a master’s degree in mechanical engineering. In re Biomet M2a Magnum Hip Implant Prods. Liab. Litig., 2017 WL 10845178, *10 (N.D. Ind. Dec. 21, 2017). The MDL court previously denied defendants’ motion to exclude Truman from offering the following general opinions: (1) all metal-on-metal devices are defectively designed; (2) metal-on-polyethylene devices are a reasonably safe alternative to metal-on-metal devices; (3) defendants should have conducted additional testing of its metal-on-metal devices; (4) defendants should have provided additional and more aggressive warnings to surgeons about the risks associated with its metal-on-metal devices; (5) defendants downplayed the risks of its metal-on-metal devices; and (6) excessive metal ions cause certain clinical effects in patients with metal-on-metal devices. Id. at *11-15. In a case-specific report, Truman now offers additional opinions regarding plaintiff’s particular implant. (Doc. #124-1, pp. 19-226.) In its motion, defendants seek to preclude Truman from offering several of these opinions, including (1) four biomechanical opinions, (2) five new common-issue opinions, and (3) any medical-causation opinions. (Doc. #124, pp. 7-17.) The Court will address each of these in turn. (1) Biomechanical Opinions a. Amount and Rate of Wear
In her report, Truman examined the rate of wear in plaintiff’s implant by creating a 3D model of the device’s head and cup. (Doc. 124-1, p. 64.) Truman estimated the implant had a total wear volume of 719 mm3, or approximately 89.9 mm3 per year it was implanted. (Id.) Using wear volume measurements provided by defendants, Truman determined plaintiff’s “M2a Magnum bearings surface experienced greater than advertised wear and therefore greater than expected wear.” (Id.) At her deposition, Truman testified that in physically examining plaintiff’s device, “it was pretty obvious in looking at the cup that there was uneven wear on that cup.” (Doc. #124-2, p. 309.) Because the wear was “so obvious” and “excessive,” Truman did not feel it was necessary to have physical measurements. (Id. pp. 274, 309.) Instead, Truman “estimate[d] a ballpark quantity based on some rough dimensions,” as described in her report. (Id. pp. 274-75.) Defendants seek to exclude Truman’s opinion because she “performed no physical measurements,” and her opinion “is based largely on a speculative ‘visual’ assessment of the device at issue.” (Doc. #124, p. 7.) The Court disagrees that Truman’s assessment is speculative, since it is based on physical examination of plaintiff’s device. See Hardison v. Biomet, Inc., 2020 WL 4334108, *12 (M.D. Ga. July 27, 2020) (noting that Truman’s opinion was “based on more than mere speculation after visually inspecting the device”). The Court finds defendants’ argument goes to the weight of Truman’s opinion, and not its admissibility. See Bayes v. Biomet, Inc., 2020 WL 5594059, *5 (E.D. Mo. Sept. 18, 2020) (“That Truman did not . . . confirm these opinions with testing of the implant goes to the weight, rather than the admissibility, of her opinions.”) The Court’s conclusion is bolstered by the evidence presented by defendants’ own expert, who calculated a substantially similar wear rate. (Doc. #132-2, p. 47) (calculating a loss rate of 88.5 mm3 per year). Accordingly, defendants’ request to exclude Truman’s opinion as to the amount and rate of wear is denied. b. Separation, Migration, and Third-Body Wear In her report, Truman offered various opinions on the condition of plaintiff’s implant, noting “evidence of cup damage and third body wear of the bearings.”1 (Doc. #124-1, p. 49 n.6.)
Truman also opined that due to the cup’s position, there was “edge loading” in plaintiff, and likely “head separation.”2 (Id.) The report also cited evidence from one of plaintiff’s doctors that the device had migrated after it was implanted. (Id. p. 47.) Defendants seek to exclude Truman’s opinions on head separation, migration, and third-body wear. (Doc. #124, pp. 8-10.) Defendants argue that Truman’s opinion that head separation occurred is speculative. (Id.) The Court disagrees. Truman’s report indicated the device likely had head separation due to plaintiff’s reported hearing of a clicking noise after the implant was in place for eight years. (Doc. #124-1, p. 49 n.6.) At her deposition, Truman conceded she “didn’t see significant evidence” of head separation, but testified that the clicking noise was consistent with it. (Doc. #124-2, p. 322-23.) Her report also
1, p. 49 n.6), and Truman testified that “a lot” of the damage to the device was “due to third body wear” (Doc. #124-2, pp. 324-25). The Court finds this evidence admissible and will deny defendants’ request.
Without the actual print or manufacturing records for plaintiff’s implant, or the ability to examine the devices’ tapers, Truman was not able to tell where those devices fell within the tolerance range. (Id. p. 303.) Accordingly, Truman agreed that “we don’t know what the actual taper mismatch would have been for [plaintiff’s] devices in their manufactured condition.” (Id. pp. 303-04.) Defendants argue Truman’s opinion should be excluded as “entirely speculative” because “she performed no measurements on [plaintiff’s] device to determine if a mismatch even existed here.” (Doc. #124, pp. 11-12.) The Court agrees. Because Truman used the production prints for the implant rather than the actual measurements of plaintiff’s device, Truman’s opinion that plaintiff’s device contained a taper mismatch outside of the acceptable range is speculative. See Hardison, 2020 WL 4334108, *13 (excluding Truman’s taper mismatch opinion as “overly speculative” because it related to the device generally and not the plaintiff’s specific device). Accordingly, the Court will grant defendants’ request to exclude this testimony. d. Corrosion In her report, Truman stated that plaintiff’s “Magnum head could not be removed due to CCW [clinical cold welding] and corrosion product is visually evident at the base of the tapers.”5 (Doc. #124-1, p. 68.) She also cited scientific literature discussing corrosion and its effects. (Id. pp. 68-69.) At her deposition, Truman reiterated that there was corrosion, but admitted she could not say how much there was or whether “it was severe or just a little bit.” (Doc. #124-2, p. 327.) Defendants argue Truman’s opinion regarding corrosion should be inadmissible “because she did not perform any testing,” but
The MDL court previously determined Truman was qualified to offer opinions on the adequacy of defendants’ warnings. In re Biomet, 2017 WL 10845178, *13. In an MDL common-issue report, Truman offered opinions applicable to the family of devices known as M2a devices, as well as the specific M2a Magnum device which plaintiff received. (Doc. #124-2, p. 248.) In her case-specific report, Truman opined that defendants “did not have sufficient warnings to alert surgeons concerning the appropriate installation position” of the M2a Magnum device to minimize various risks. (Doc. #124-1, p. 138.) Defendants argue that because Truman did not offer this opinion in her common-issue report, she cannot offer it now. (Doc. #124, pp. 13-14.) The Court agrees.
In her common-issue report, Truman’s opinion regarding the appropriate installation position and defendants’ failure to warn was specific to the M2a-38 device, not the M2a Magnum device. (Doc. #124-2, pp. 372-74.) Truman acknowledged as much at her deposition, agreeing that her case-specific opinion was “slightly different” than her MDL opinion, as she had “been working on some other M2a-38 reports and . . . had specifically used that one.” (Id. p. 374.) Plaintiff argues that because Truman’s MDL opinions related to the family of M2a devices, her more specific opinion regarding the M2a Magnum falls within the MDL general opinions. (Doc. #132, pp. 9-10.) The Court disagrees. Truman’s MDL opinion was specific to a device within the M2a family, and that device was not the M2a Magnum. Accordingly, to the extent Truman now applies that opinion to the M2a Magnum, it is a new common-issue opinion and inadmissible. See Bayes, 2020 WL 5594059, *4 (“[To] the extent Biomet seeks to exclude common-issue opinions included in Truman’s MDL report, the Court denies the motion. Conversely, to the extent Truman’s rebuttal report includes new or different common-issue opinions not included in her MDL report, the Court grants Biomet’s motion to exclude those opinions.”). b. Cold Welding In her case-specific report, Truman opined that the M2a Magnum had “several warning defects,” and specifically that defendants “did not warn of cold welding in the M2a Magnum.” (Doc. #124-1,
p. 142.) The Court agrees with defendants that this is a commonissue opinion that should have been provided in Truman’s MDL report. (Doc. #124, p. 14.) At her deposition, Truman acknowledged that while her MDL report discussed warnings “at some length,” “[t]he cold welding issue wasn’t brought up in the MDL.” (Doc. #124-2, p. 392.) While Truman testified that the opinion was specific to plaintiff “because he had clinical cold welding in his devices,” she agreed that “[t]his is a general opinion that relates to what [she] see[s] as warning failures, not only warning failures that only occurred in [plaintiff’s] case.” (Id. p. 393.) Because Truman’s opinion is a novel common-issue opinion, the Court will exclude it.6 c. Assembly Instructions and Tools
Truman opined that defendants failed to provide assembly instructions or specialized tools, and that this constituted system design and warning defects in the Magnum system. (Doc. 124-1, p. 142.) Because plaintiff concedes this opinion is not relevant to this case (Doc. #132, p. 10), the Court will grant defendants’ request to exclude it (Doc. #124, p. 14). d. Positional Tradeoffs In her case-specific report, Truman opined that “[p]ositioning of total hip bearings involves tradeoffs,” and that surgeons are justified in attempting to restore the normal biomechanics of the patient’s hip joint using standard techniques unless they are clearly informed in advance of surgery by a THA [total hip arthroplasty] prothesis manufacturer that use of a specific implant design may fail and cause patient harm when used outside a specific and more restricted envelope.
(Doc. #124-1, pp. 143-44.) Truman further opined that defendants “should have told surgeons about the risk of edge loading,
issue opinion, and therefore should be excluded. (Doc. #124, p. 14.) The Court agrees in part. Truman’s opinion on this issue is actually two separate opinions. First, Truman opines that a surgeon is justified in attempting to restore normal biomechanics of a hip joint unless warned otherwise by a prothesis manufacturer. Plaintiff argues this is a case-specific opinion because defendants “contend[] that the excessive wear of metal ions in Plaintiff was caused by malpositioning of the Magnum device at implant.”7 (Doc. #132, p. 10.) The Court disagrees. Truman’s opinion is not specific to the surgeon who implanted the device in plaintiff, but rather applies to all surgeons conducting hip implants. Accordingly, the opinion is a common-issue opinion. Furthermore, because it seems undisputed that Truman did not offer this opinion in her prior MDL report, the Court will grant defendants’ request to exclude it. Truman has also opined that defendants should have warned surgeons regarding potential dangers if the implant was inserted
The Court finds these opinions substantially the same as the opinion offered in Truman’s case-specific report, and therefore the latter cannot be considered “new.” Accordingly, the Court declines to exclude this portion of the opinion.
. . .
Biomet also should have had the knowledge concerning appropriate inclination and anteversion angles for MoM [metal-on-metal] articulations and should have shared information concerning the risks and should have taught against, warned about or contraindicated installation in angles > ~ 50˚ and combined anteversion > 25˚ but did not do so. These instructions should have been in their surgical techniques and other training materials.
In re Biomet M2a Magnum Hip Implant Prods. Liab. Litig., MDL-2391 (Doc. #3387-2, pp. 126, 139.) e. Cup Orientation and Stability In her case-specific report, Truman opined that “[w]hen the cup is oriented to improve not only stability, but also wear . .
., there was little or no added stability achieved by the use of femoral heads larger than 36mm.” (Doc. #124-1, p. 144.) At her deposition, Truman agreed this was “a general statement, a common opinion” that did not specifically apply to plaintiff, but also noted she “did discuss this in [her] MDL [report] also.” (Doc. 124-2, pp. 439-40.) Plaintiff concedes that Truman’s opinion is not relevant to her specific findings in this case, but nonetheless argues it “is allowable as a general opinion because the MDL Judge struck none of Ms. Truman’s general opinions.” (Doc. #132, p. 11.) To the extent Truman offered this opinion in her MDL report9, the Court will decline defendants’ request to exclude it as a new common-issue opinion. (3) Medical-Causation Opinions
Finally, defendants seek to preclude Truman from offering medical-causation opinions due to her lack of appropriate qualifications. (Doc. #124, pp. 15-17.) Because plaintiff
B. George Kantor
George Kantor is a board-certified orthopedic surgeon, specializing in hip, knee, and shoulder replacement, and has performed roughly5,000 total hip arthroplasty procedures over the course of his career. In re Biomet, 2017 WL 10845178, *15. The MDL court previously denied defendants’ motion to exclude Kantor from offering the following general opinions: (1) metal-on-metal devices generally are defectively designed and their risks outweigh their benefits; (2) defendants’ instructions for use were inadequate; and (3) elevated metal ions might cause cancer. Id. at *15-18. Kantor has now prepared a case-specific report which offers a variety of opinions and concludes that plaintiff “has sustained permanent and irreversible damage” because of the implant. (Doc. 125-4, p. 168.) Defendants seek to exclude several of Kantor’s opinions, including the following: (1) plaintiff’s implant caused plaintiff’s injuries; (2) edge loading or impingement did not cause plaintiff’s elevated cobalt-chromium levels; (3) a component of plaintiff’s device caused his elevated cobalt-chromium levels; (4) plaintiff experienced cobalt and chromium toxicity; and (5) plaintiff will need future medical treatments and surgeries. (Doc. #125, pp. 6-23.) The Court will address each of these in turn. (1) Specific Causation
As noted, Kantor opines that plaintiff has sustained permanent damage caused by defendants’ implant. (Doc. #125-2, p. 168.) Defendants seek to exclude this opinion on the grounds that it is “derived from an unreliable methodology.” (Doc. #125, p. 6.) Specifically, defendants argue Kantor “failed to give due consideration to obvious alternative causes,” such as malposition of the device. (Id. pp. 7-14.) Having reviewed the arguments of the parties, as well as Kantor’s case-specific report and deposition testimony, the Court disagrees. The issue essentially boils down to whether Kantor conducted a sufficient differential diagnosis in determining the cause of plaintiff’s injuries. (Id. p. 7.) A “[d]ifferential diagnosis is accomplished by determining the possible causes for the patient’s symptoms and then eliminating each of these potential causes until reaching one that cannot be ruled out or determining which of those that cannot be excluded is the most likely.” Guinn v. AstraZeneca Pharm. LP, 602 F. 3d 1245, 1253 (11th Cir. 2010) (marks and citation omitted)). “When properly conducted, a differential diagnosis can be a reliable methodology under Daubert.” Id. However, “an expert does not establish the reliability of his techniques or the validity of his conclusions simply by claiming that he performed a differential diagnosis on a patient.” Id. (citation omitted). Furthermore, while “a reliable differential diagnosis need not rule out all possible alternative causes, it must at least consider other factors that could have been the sole cause of the plaintiff’s injury.” Id.; see also Redd v. DePuy Orthopaedics, Inc., 700 Fed. App’x 551, 554 (8th Cir. 2017) (“Although . . . an expert need not rule out all possible causes of an injury, an expert nonetheless should ‘adequately account[] for obvious alternative explanations.’” (quoting Fed. R. Evid. 702 advisory committee notes to 2000 amendment)). Defendants argue that Kantor’s differential diagnosis is unreliable because he “improperly rules out malposition as an alternative cause” of plaintiff’s injuries.10 (Doc. #125, p. 9.) The Court must first determine whether Kantor was required to consider malposition at all prior to determining whether Kantor erred in ruling out malposition as an alternative cause. As noted, a causation expert need only account for “obvious alternative explanations.” Redd, 700 Fed. App’x at 554. Accordingly, if the improper positioning of the device does not
(Id. pp. 161-62.) At his deposition, Kantor testified that his opinion that there was no evidence of malposition was based on his measurements and his review of x-rays taken during the surgery, as well as x-rays taken one week, two weeks, six months, and eighteen months after the surgery. (Doc. #125-5, pp. 329-30.) Kantor testified that his opinion was also informed by his experience “looking at thousands and thousands and thousands of hips.” (Id. p. 339.) Based on this evidence, the Court finds Kantor adequately considered whether plaintiff’s implant was in a malposition, and therefore defendants’ argument to exclude his specific causation opinion fails. See Bayes, 2020 WL 5095346, *8 (rejecting argument that Kantor did not “adequately account for the position of the left acetabular cup” because Kantor “denies that the left cup was out of position at all,” and defendant’s criticisms in how Kantor came to that conclusion “go to the weight, rather than the admissibility, of Kantor’s causation opinion”).12
378-79, 417, 419.) He also testified that plaintiff’s metal ion levels would not be consistent with either edge loading or impingement of the device. (Id. pp. 416, 419.) Defendants seek to exclude these opinions on the grounds that Kantor never analyzed plaintiff’s device, and therefore the opinions “are based on nothing more than assumptions.” (Doc. #125, p. 15.) The Court disagrees. Defendants’ argument is premised on its assertion that “Kantor concedes that an analysis of [plaintiff’s] device is necessary to determine whether impingement or edge loading contributed to [plaintiff’s] cobalt-chromium levels.” (Id.) However, the evidence does not support this assertion. During his deposition, Kantor conceded that he had not examined plaintiff’s device or spoke with Truman about her opinions. (Doc. #125-5, p. 316.) He also noted that he would like to examine the device in the future, which may provide additional information regarding the generation of metal ions and the device’s wear patterns. (Id. pp. 319-20.) He stated he “would be curious to see if there is equatorial edge loading” due to the design of the implant, and that an analysis of the device “has some relevance.” (Id. pp. 321, 322.) Nonetheless, he specifically testified that his casespecific opinions did not require visual inspection of plaintiff’s implant, and that he was able to stand by those opinions with a reasonable degree of medical certainty without performing a visual inspection. (Id. p. 486.) Kantor clarified that his desire to examine the device was “more for intellectual curiosity as opposed to anything substantive or anything that [he] would change in [his] report.” (Id. pp. 486-87.) Thus, Kantor did not testify that a physical examination of the device was necessary to determine whether edge loading or impingement caused plaintiff’s metal-ion levels, and he stated such an examination was unnecessary for any of his opinions. The Court therefore denies defendants’ motion to exclude on this issue. To the extent it is relevant, defendants may raise Kantor’s failure to examine the device on cross-examination. See Bayes, 2020 WL 5594059, *5 (expert’s inability to examine device to confirm her opinions “goes to the weight, rather than the admissibility, of her opinions”). (3) Cause of Elevated Cobalt-Chromium Levels During his deposition, Kantor testified plaintiff’s metalion levels were “frighteningly high,” and offered four potential sources of the ions. (Doc. #125-5, p. 417.) One such source was corrosion of the device’s “mixed-metal coupling.” (Id. pp. 417- 18.) Defendants seek to exclude this opinion as “entirely unsupported by scientific or factual evidence.” (Doc. #125, p. 16.) Specifically, defendants argue that the components of the coupling at issue cannot be the source of cobalt-chromium ions because they are made of a titanium alloy, not mixed metals. (Id. pp. 16-17.) The Court agrees. The Court will exclude Kantor’s opinion that the titanium alloy components of the device caused plaintiff’s elevated cobalt-chromium levels. See Gen. Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997) (“[N]othing in either Daubert or the Federal Rules of Evidence requires a district court to admit opinion evidence that is connected to existing data only by the ipse dixit of the expert. A court may conclude that there is simply too great an analytical gap between the data and the opinion proffered.”); McDowell v. Brown, 392 F. 3d 1283, 1299 (11th Cir. 2004) (noting there must be a “fit” with respect to the offered opinion and the facts of the case, and “there is no fit where a large analytical leap must be made between the facts and the opinion”).13
(Doc. #125-5, p. 387.) Defendants argue Kantor misrelies on the Plummer and Jacobs article because it “merely provides a guideline cobalt level to assist in the diagnosis of corrosion in a metalon-polyethylene device,” and “it certainly does not establish a baseline for abnormal levels of cobalt-chromium.” (Doc. #125, p. 20.) In the article, which defendants attached as an exhibit to their motion, the authors reviewed twenty-seven patients who underwent revision for an adverse local tissue reaction secondary to corrosion of a metal-on-polyethylene device. (Doc. #125-9, p. 783.) The authors examined the patients’ preoperative cobalt and chromium levels, which were elevated in each patient, and concluded that “serum metal levels are a good initial screening test” for a corrosion diagnosis. (Id. pp. 785, 786.) In doing so, the authors stated that in evaluating serum metal levels, “anything greater than1 [part per billion] is considered abnormal.” (Id. p. 786.) The Court finds this sufficient support for Kantor’s opinion that “serum metal ion levels above1 are abnormal,” and therefore denies defendants’ request to exclude the testimony.
Defendants also seek to preclude Kantor from testifying about the systemic effects of cobalt and chromium toxicity. (Doc. #125, pp. 18-19.) During his deposition, Kantor testified that plaintiff’s cobalt and chromium levels were “catastrophically” and “frighteningly high.” (Doc. #125-5, p. 387.) When asked what systemic effects occur as a result of cobalt toxicity, Kantor identified cardiovascular issues, central nervous system effects, and thyroid problems. (Id. pp. 390-91.) Defendants argue that because it is undisputed plaintiff has not suffered from any of these, Kantor should be precluded from testifying about the systemic effects of cobalt and chromium toxicity. (Doc. #125, pp. 18-19); see also Bayes, 2020 WL 5594059, *4 (finding expert’s opinion regarding clinical cold welding was irrelevant and would not assist the jury if the patient did not experience clinical cold welding). The Court disagrees. In addition to the above, Kantor also identified “excessive fatigue” and musculoskeletal problems as symptoms of cobalt toxicity, both of which plaintiff has experienced. (Doc. #125-5,
pp. 391-93.) Kantor also testified that while plaintiff has “been very fortunate” in the symptoms he’s experienced, “the jury is not out in terms of the development of systemic effects.” (Id. pp. 391, 392.) Because Kantor has linked plaintiff’s symptoms with the systemic effects of ion toxicity, the Court will deny defendants’ request to exclude the opinion at issue. Defendants may use plaintiff’s limited symptoms to challenge the opinion that plaintiff is suffering from the systemic effects of cobalt or chromium toxicity. (5) Future Medical Care Finally, defendants seek to preclude Kantor from opining on plaintiff’s future medical care. (Doc. #125, pp. 21-23.) The parties agree that an award for future medical damages requires such damages be reasonably certain. (Id.; Doc. #134, p. 18); see also Montesinos v. Zapata, 43 So. 3d 97, 99 (Fla. 3d DCA 2010) (“[A]n award of future economic damages is appropriate ‘when such damages are established with reasonable certainty.’” (quoting Auto-Owners Ins. Co. v. Tompkins, 651 So. 2d 89, 91 (Fla. 1995)). It is plaintiff’s burden to establish that future medical expenses “will more probably than not be incurred,” and that burden “will only be met with competent substantial evidence.” Montesinos, 43 So. 3d at 99 (citations omitted). In his report, Kantor discussed the potential problems that may arise due to a failed metal-on-metal implant, noting the following: When MoM implant failure occurs in this manner, necrosis of the bone, tendons and tissue can be a direct result of the premature failure of the device. This outcome can result in permanent damage to the bone and soft tissues adjacent to the patient’s implant, which is irreversible.
Complications resulting from the premature failure of the MoM implants, such as the Biomet MoM hip implants, include the likelihood of a patient needing multiple future revision surgeries with increasing complexities of those revision procedures to be expected, especially in light of the bone and tissue damage that often accompany the failure of a MoM hip implant. In comparison to MoP [metal-on-polyethylene] or CoP [ceramic-on- polyethylene] alternatives, there is a significantly increased risk of dislocations, infections, and peri- prosthetic pathologic fractures published in multiple joint registries in countries following the sub set of MoM prosthetic implant systems.
(Doc. #125-4, p. 159.) With regards to plaintiff specifically, Kantor made the following conclusion: Because of the extensive bone necrosis/destruction [plaintiff] is at risk for periprosthetic fracture to both the pelvic and femoral bones that serve as the foundation for his THA. These complications are well documented in the literature and are common in my practice and all hip surgeons undertaking complex removal and revision of MoM THA systems. Due to his relatively young age at index surgery (55 years) he will unfortunately have to deal with these issues in the future. He will in all likelihood require even more difficult reconstructive revision procedures that are associated with increased risk and well documented complications. Future revision and reconstructive procedures to his right hip will require addressing the ongoing osteolysis (bone loss) that is progressive and compromising the acetabular and femoral bone foundation of his total hip arthroplasty construct. The osteolysis and bone destruction that the patient has and is currently experiencing must be evaluated on a regular basis even if his symptoms are currently minimal. The risk of peri-prosthetic fracture in these cases is well documented and unfortunately difficult technically for the revision surgeon to correct. Radiographic studies including plain films, CAT Scans and special MRIs are of paramount importance for assessment of progressive metal ion disease and its future destruction to the bone and soft tissues of the right THA of [plaintiff].
(Id. pp. 168-69.) Defendants argue that Kantor should be prevented from offering any opinions on plaintiff’s future medical care because such opinions are speculative. (Doc. #125, pp. 21-23.) This argument is based on defendants’ assertion that Kantor’s deposition testimony demonstrates he was either unable to offer an estimate on the possibility of future revision surgeries, or offered an estimate below fifty percent. (Id. p. 22.) The Court finds defendants have misinterpreted the testimony. At the deposition, Kantor testified that if the estimates of plaintiff’s life expectancy based on actuarial charts were accurate, “there is no question that he will have additional surgery.” (Doc. #125-5, p. 474.) Kantor further explained that he believed “the primary problem” was going to be a periprosthetic fracture, and estimated there was a twenty to forty percent chance of a revision surgery due to such a fracture. (Id. pp. 474-76.) He also stated he was unable to answer whether revision surgery would be needed due to a dislocation, and that there was a ten to twenty percent chance plaintiff would need the surgery due to an infection. (Id. pp. 478-79.)
The Court agrees with plaintiff that taken together, Kantor’s testimony establishes that plaintiff will require a future revision surgery, the cause of which currently cannot be stated with certainty. (Doc. #134, p. 18.) To the extent Kantor qualified his opinion about the need for a future surgery, such a qualification goes to the opinion’s weight and not admissibility. See White v. Westlund, 624 So. 2d 1148, 1151 (Fla. 4th DCA 1993) (“[W]hatever qualification is placed on the opinion by the expert (i.e., surgery is possible or likely) goes to the weight of the opinion, and not its admissibility. Therefore, we agree that a medical expert may testify that future medical procedures are ‘possible’ or ‘likely,’ and need not phrase an opinion in terms of such surgery or treatment being ‘reasonably necessary.’”). Based on Kantor’s report describing the likely complications metal-onmetal hip implant patients experience and the likelihood plaintiff will require a future revision surgery, as well as Kantor’s testimony that “there is no question” such a surgery will be required, the Court finds Kantor’s opinions are reasonably certain. Accordingly, the Court denies defendants request to exclude Kantor’s future medical care opinions.14 Accordingly, it is hereby ORDERED: Defendants’ Motion to Exclude the Opinions and Testimony of Mari Truman and Memorandum in Support (Doc. #124) and Motion to
Exclude the Opinions and Testimony of George S. Kantor, M.D. and Memorandum in Support (Doc. #125) are GRANTED in part and DENIED in part as set forth above.
Z tkteol
JQH E. STEELE
5 IOR UNITED STATES DISTRICT JUDGE Copies: Counsel of Record
Cases With Similar Vibessemantic neighbors from the corpus
Citator
Cited By
-
Fitzsimmons v. Biomet Orthopedics, 896 F. Supp. 2d 1339 (M.D. Fla. 2020)…s filed against defendants, was consolidated for pretrial proceedings into a Multi-District Litigation (MDL) action in the United States District Court for the Northern District of Indiana. In re: Biomet M2A Magnum Hip Implants Prods. Liab. Litig., 896 F. Supp. 2d 1339 (J.P.M.L. 2012). After considerable pretrial proceedings in the MDL court, including rulings on motions to exclude common-issue expert opinions, this case was transferred back to this district in February 2019. (Doc. #56; Doc.…
-
Fitzsimmons v. Biomet Orthopedics (M.D. Fla. 2021)…filed against Biomet, was consolidated for pretrial proceedings into a Multi-District Litigation (MDL) action in the United States District Court for the Northern District of Indiana. In re: Biomet M2A Magnum Hip Implants Prods. Liab. Litig., 896 F. Supp. 2d 1339 (J.P.M.L. 2012). After considerable pretrial proceedings in the MDL court, the case was transferred back to this district in February 2019. (Doc. #56; Doc. #57.) The parties then engaged in case-specific discovery until September 2020, and…
Authorities Cited (11 total)
- Daubert et ux. v. Merrell Dow Pharms., Inc., 509 U.S. 579 (U.S. 1993)
- United States v. Frazier, 387 F.3d 1244 (11th Cir. 2004)
- Gen. Elec. Co. v. Joiner et ux., 522 U.S. 136 (U.S. 1997)
- Roderic R. McDOWELL v. Pernell Brown, 392 F.3d 1283 (11th Cir. 2004)
- McCORVEY v. Baxter Healthcare Corp., 298 F.3d 1253 (11th Cir. 2002)
- Auto-Owners Ins. Co. v. Tompkins, 651 So. 2d 89 (Fla. 1995)
- White v. Westlund, 624 So. 2d 1148 (Fla. 4th DCA 1993)
- Tampa BAY Water v. HDR Eng'g, Inc., 731 F.3d 1171 (11th Cir. 2013)
- Guinn v. Astrazeneca Pharms. LP, 602 F.3d 1245 (11th Cir. 2010)
- Montesinos v. Zapata, 43 So. 3d 97 (Fla. 3d DCA 2010)